FRE Stock Overview
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.99 |
| 52 Week High | €31.15 |
| 52 Week Low | €24.06 |
| Beta | 1.08 |
| 1 Month Change | 12.14% |
| 3 Month Change | 7.00% |
| 1 Year Change | 10.02% |
| 3 Year Change | -30.46% |
| 5 Year Change | -43.13% |
| Change since IPO | 2,379.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| FRE | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 0.3% | -1.4% |
| 1Y | 10.0% | 2.1% | 2.2% |
Return vs Industry: FRE exceeded the German Healthcare industry which returned -1.8% over the past year.
Return vs Market: FRE exceeded the German Market which returned 1.9% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 3.1% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months.
Volatility Over Time: FRE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 193,865 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | €15.75b |
| Earnings (TTM) | €353.00m |
| Revenue (TTM) | €22.30b |
44.6x
P/E Ratio0.7x
P/S RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | €22.30b |
| Cost of Revenue | €17.24b |
| Gross Profit | €5.06b |
| Other Expenses | €4.71b |
| Earnings | €353.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 0.63 |
| Gross Margin | 22.68% |
| Net Profit Margin | 1.58% |
| Debt/Equity Ratio | 70.4% |
How did FRE perform over the long term?
See historical performance and comparison